How does diabetes accelerate atherosclerotic plaque rupture and arterial occlusion?

Frontiers in Bioscience

Volumn 8, Issue SUPPL., 2003, Pages

  Schwartz, Stephen M ^a   Bornfeldt, Karin E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atherosclerosis; Inflammation; Matrix metalloproteinases; Mouse models; Review; Thrombosis

Indexed keywords

CATHEPSIN; MATRIX METALLOPROTEINASE;

APOPTOSIS; ARTERY OCCLUSION; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL DEATH; CYTOPATHOLOGY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; EXPERIMENTAL ANIMAL; FIBRINOLYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; MACROPHAGE; MORTALITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOOTH MUSCLE FIBER; THROMBOGENESIS; THROMBOGENICITY; ANIMAL; ARTERIOSCLEROSIS; DISEASE MODEL; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RUPTURE;

ANIMALIA;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; RUPTURE, SPONTANEOUS;

EID: 3142766302     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Ferrier T.M: Comparative study of arterial disease in amputated lower limbs from diabetics and non-diabetics (with special reference to feet arteries). Med J Aust 1, 5-11 (1967)
2. Virmani R, F.D. Kolodgie, A.P. Burke, A. Farb & S.M. Schwartz: Lessons from sudden coronary death. Arterioscler Thromb Vasc Biol 20, 1262-1275 (2000)
3. Ruderman N.B. & C. Haudenschild: Diabetes as an atherogenic factor. Prog Cardiovasc Dis 26, 373-412 (1984)
4. Silva J.A, A. Escobar, T.J. Collins, S.R. Ramee & C.J. White: Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 92, 1731-1736 (1995)
5. DCCT; The Diabetes Control and Complications Trial Research Group: The effects of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 329, 977-986 (1993)
6. UKPDS Group: Intensive blood-glucsoe control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352, 837-853 (1998)
7. Duckworth W.C: Hyperglycemia and cardiovascular disease. Curr Atheroscler Rep 3, 383-391 (2001)
8. Khaw K.T, N. Wareham, R. Luben, S. Bingham, S. Oakes, A. Welch & N. Day: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322, 15-18 (2001)
9. Harding A.H, L.A. Sargeant, A. Welch, S. Oakes, R.N. Luben, S. Bingham, N.E. Day, K.T. Khaw & N.J. Wareham: Fat consumption and HbA(1c) levels: the EPIC-Norfolk study. Diabetes Care 24, 1911-6 (2001)
10. Taskinen M.R: Diabetic dyslipidemia. Atheroscler Suppl 3, 47-51 (2002)
11. Reaven G.M: Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes Metab 4 Suppl 1, S13-S18 (2002)
12. Ruotolo G. & B.V. Howard: Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 4, 494-500 (2002)
13. Yki-Järvinen H: Management of type 2 diabetes mellitus and cardiovascular risk. Drugs 60, 975-983 (2001)
14. Steiner G: Treating lipid abnormalities in patients with type 2 diabetes mellitus. Am J Cardiol 88, 12 Suppl 1, 37-40 (2001)
15. Robins S.J: Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol 88, 12 Suppl 1, 19-23 (2001)
16. Huang E.S, J.B. Meigs & D.E. Singer: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111, 633-642 (2001)
17. Gotto A.M: Lipid management in diabetic patients: lessons from prevention trials. Am J Med 112 Suppl 8A, 19S-26S (2002)
18. Ginsberg H.N: Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care 14, 839-55 (1991)
19. Dunn F.L: Plasma lipid and lipoprotein disorders in IDDM. Diabetes 41, Suppl 2, 102-106 (1992)
20. Garg A: Management of dyslipidemia in IDDM patients. Diabetes Care 17, 224-234 (1994)
21. Weinstock Brown W. & W.F. Keane: Proteinuria and cardiovascular disease. Am J Kidney Dis 38, 4 Suppl 1, S8-S13 (2001)
22. Dullaart R.P: Plasma lipoprotein abnormalities in type 1 (insulin-dependent) diabetes mellitus. Neth J Med 46, 44-54 (1995)
23. HOPE study investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259 (2000)
24. Stary H.C, A.B. Chandler, R.E. Dinsmore, V. Fuster, S. Glagov, W.Jr. Insull, M.E. Rosenfeld, C.J. Schwartz, W.D. Wagner & R.W. Wissler: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council of Atherosclerosis, American Heart Association. Circulation 92, 1355-1374 (1995)
25. Williams K.J. & I. Tabas: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15, 551-561 (1995)
26. Libby P: Inflammation in atherosclerosis. Nature 420, 868-874 (2002)
27. Glass C.K. & J.L. Witztum: Atherosclerosis. The road ahead. Cell 104, 503-516 (2001)
28. Pratico D, R.K. Tangirala, S. Horkko, J.L. Witztum, W. Palinski & G.A. FitzGerald: Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F(2alpha)-VI levels and the extent of atherosclerosis in ApoE-deficient mice: modulation by vitamin E. Blood 97, 459-464 (2001)
29. Hansson G.K, P. Libby, U. Schonbeck & Z.Q. Yan: Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91, 281-291 (2002)
30. Zhou X, G. Paulsson, S. Stemme & G.K. Hansson: Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 101, 1717-1725 (1998)
31. Mehrabian M, H. Allayee, J. Wong, W. Shih, X.P. Wang, Z. Shaposhnik, C.D. Funk & A.J. Lusis: Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91, 120-126 (2002)
32. Dixon J.L, J.D. Stoops, J.L. Parker, M.H. Laughlin, G.A. Weisman & M. Sturek: Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Arterioscler Thromb Vasc Biol 19, 2981-2992 (1999)
33. Renard C.B, L.A. Suzuki, F. Kramer, L.R. Tannock, M.G. von Herrath, A. Chait & K.E. Bornfeldt: A new murine model of diabetes-accelerated atherosclerosis. Diabetes 51, suppl. 2, 724 (2002)
34. Simionescu M, D. Popov, A. Sima, M. Hasu, G. Costache, S. Faitar, A. Vulpanovici, C. Stancu, D. Stern & N. Simionescu: Pathobiochemistry of combined diabetes and atherosclerosis studied on a novel animal model. The hyperlipemic-hyperglycemic hamster. Am J Pathol 148, 997-1014 (1996)
35. McGill H.C.Jr, C.A. McMahan, G.T. Malcom, M.C. Oalmann & J.P. Strong: Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 15, 431-440 (1995)
36. McGill H.C.Jr, C.A. McMahan, A.W. Zieske, G.T. Malcom, R.E. Tracy & J.P. Strong: Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 103, 1546-1550 (2001)
37. Järvisalo M.J, A. Putto-Laurila, L. Jartti, T. Lehtimäki, T. Solakivi, T. Rönnemaa & O.T. Raitakari: Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 51, 493-498 (2002)
38. Virchow R: Cellular Pathology as based upon physiological and pathological histology. Classics of Medicine Library, Birmingham, Alabama (1855)
39. Kozaki K, W.E. Kaminski, J. Tang, S. Hollenbach, P. Lindahl, C. Sullivan, J.C. Yu, K. Abe, P.J. Martin, R. Ross, C. Betsholtz, N.A. Giese, & E.W. Raines: Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. Am J Pathol 161, 1395-1407 (2002)
40. Sano H, T. Sudo, M. Yokode, T. Murayama, H. Kataoka, N. Takakura, S. Nishikawa, S.I. Nishikawa & T. Kita: Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 103, 2955-2960 (2001)
41. Yao P.M. & I. Tabas: Free cholesterol loading of macrophages induces apoptosis involving the Fas pathway. J Biol Chem 275, 23807-23813 (2000)
42. Yao P.M. & I. Tabas: Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J Biol Chem 276, 42468-42476 (2001)
43. Virmani R, A.P. Burke, A. Farb & F.D. Kolodgie: Pathology of the unstable plaque. Prog Cardiovasc Dis 44, 349-356 (2002)
44. Libby P: Inflammation in atherosclerosis. Nature 420, 868-874 (2002)
45. Davies MJ: Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94, 2013-2020 (1996)
46. Galis Z.S, G.K. Sukhova, M.W. Lark & P. Libby: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94, 2493-2503 (1994)
47. Saren P, H.G. Welgus & P.T. Kovanen: TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 157, 4159-4165 (1996)
48. Lemaître V, T.K. O'Byrne, A.C. Borczuk, Y. Okada, A.R. Tall & J. D'Armiento: ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 107, 1227-1234 (2001)
49. Lemaître V, Soloway PD, D'Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 107, 333-338 (2003)
50. Lutgens E, K.B. Cleutjens, S. Heeneman, V.E. Koteliansky, L.C. Burkly & M.J. Daemen: Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 97, 7464-7469 (2000)
51. Schonbeck U, G.K. Sukhova, K. Shimizu, F. Mach & P. Libby: Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 97, 7458-7463 (2000)
52. Schonbeck U. & P. Libby: CD40 signaling and plaque instability. Circ Res 89, 1092-1103 (2001)
53. Inoue S, K. Egashira, W. Ni, S. Kitamoto, M. Usui, K. Otani, M. Ishibashi, K. Hiasa, K. Nishida & A. Takeshita: Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 106, 2700-2706 (2002)
54. Lutgens E. & M.J. Daemen: CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 12, 27-32 (2002)
55. Rosenfeld M.E, P. Polinsky, R. Virmani, K. Kauser, G. Rubanyi & S.M. Schwartz: Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol 20, 2587-2592 (2000)
56. Johnson J.L. & C.L. Jackson: Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis 154, 399-406 (2001)
57. Nakata Y. & N. Maeda: Vulnerable atherosclerotic plaque morphology in apolipoprotein E-deficient mice unable to make ascorbic acid. Circulation 105, 1485-1490 (2002)
58. Murayama T, M. Yokode, H. Kataoka, T. Imabayashi, H. Yoshida, H. Sano, S. Nishikawa & T. Kita: Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation 99, 1740-1746 (1999)
59. Rosenfeld M.E, K. Kauser, B. Martin-McNulty, P. Polinsky, S.M. Schwartz & G.M. Rubanyi: Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis 164, 251-259 (2002)
60. Rosenfeld M.E, K.G. Carson, J.L. Johnson, H. Williams, C.L. Jackson & S.M. Schwartz: Animal models of spontaneous plaque rupture: the holy grail of experimental atherosclerosis research. Curr Atheroscler Rep 4, 238-242 (2002)
61. Cullen P, R. Baetta, S. Bellostra, F. Bernini, G. Chinetti, A. Cignarella, A. von Eckardstein, A. Exley, M. Goddard, M. Hofker, E. Hurt-Camejo, E. Kanters, P. Kovanen, S. Lorkowski, W. McPheat, M. Pentikäinen, J. Rauterberg, A. Richie, B. Staels, B. Weitkamp & M. de Winther: Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol 23, 535-542 (2003)
62. Calara F, M. Silvestre, F. Casanada, N. Yuan, C. Napoli & W. Palinski: Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol 195, 257-263 (2001)
63. Zhou J, J. Møller, C.D. Danielsen, J. Bentzon, H.B. Ravn, R.C. Austin & E. Falk: Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in apoE-deficient mice. Arterioscler Thromb Vasc Biol 21, 1470-1476 (2001)
64. Williams H, J.L. Johnson, K.G.S. Carson & C.L. Jackson: Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Artherioscler Thromb Vasc Biol 22, 788-792 (2002)
65. Jolley C.D, J.M. Dietschy & S.D. Turley: Genetic differences in cholesterol absorption in 129/Sv and C57BL/6 mice: effect on cholesterol responsiveness. Am J Physiol 39, G1117-G1124 (1999)
66. von der Thüsen J.H, B.J.M. van Vlijmen, R.C. Hoeben, M.M. Kockx, L.M. Havekes, T.J.C. van Berkel & E.A.L. Biessen: Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation 105, 2064-2070 (2002)
67. Ridker P.M, N. Rifai, L. Rose, J.E. Buring & N.R. Cook: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347, 1557-1565 (2002)
68. Moreno P.R, A.M. Murcia, I.F. Palacios, M.N. Leon, V.H. Bernardi, V. Fuster & J.T. Fallon: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102, 2180-2184 (2000)
69. Bucala R, Z. Makita, T. Koschinsky, A. Cerami & H. Vlassara: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90, 6434-6438 (1993)
70. Virella G, D. Atchley, S. Koskinen, D. Zheng & M.F. Lopes-Virella: Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 105, 81-92 (2002)
71. Bucciarelli L.G, T. Wendt, W. Qu, Y. Lu, E. Lalla, L.L. Rong, M.T. Goova, B. Moser, T. Kislinger, D.C. Lee, Y. Kashyap, D.M. Stern & A.M. Schmidt: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827-2835 (2002)
72. Sakaguchi T, S.F. Yan, S.D. Yan, D. Belov, L.L. Rong, M. Sousa, M. Andrassy, S.P. Marso, S. Duda, B. Arnold, B. Liliensiek, P.P. Nawroth, D.M. Stern, A.M. Schmidt & Y. Naka: Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111, 959-972 (2003)
73. Kim J.A, J.A. Berliner, R.D. Natarajan & J.L. Nadler: Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 43, 1103-1107 (1994)
74. Schmidt A.M, O. Hori, J.X. Chen, J.F. Li, J. Crandall, J. Zhang, R. Cao, S.D. Yan, J. Brett & D. Stern: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96, 1395-1403 (1995)
75. Richardson M, S.J. Hadcock, M. DeReske & M.I. Cybulsky: Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb 14, 760-769 (1994)
76. Ribau J.C, S.J. Hadcock, K. Teoh, M. DeReske & M. Richardson: Endothelial adhesion molecule expression is enhanced in the aorta and internal mammary artery of diabetic patients. J Surg Res 85, 225-233 (1999)
77. Wong B.W, D. Wong & B.M. McManus: Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 11, 332-338 (2002)
78. Galis Z.S & J.J. Khatri: Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly. Circ Res 90, 251-262 (2002)
79. Galis Z, G. Sukhova & P. Libby: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 9, 974-980 (1995)
80. Marx N, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach & W. Koenig W: Antidiabetic PPAR□-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23, 283-288 (2003)
81. Uemura S, H. Matsushita, W. Li, A.J. Glassford, T. Asagami, K.H. Lee, D.G. Harrison & P.S. Tsao: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88, 1291-1298 (2001)
82. Portik-Dobos V, M.P. Anstadt, J. Hutchinson, M. Bannan & A. Ergul: Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 51, 3063-3068 (2002)
83. Shi G.P, J.S. Munger, J.P. Meara, D.H. Rich & H.A. Chapman: Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 267, 7258-7262 (1992)
84. Kafienah W, D. Bromme, D.J. Buttle, L.J. Croucher & A.P. Hollander: Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem J 331, 727-732 (1998)
85. Reddy V.Y, Q.Y. Zhang & S.J. Weiss: Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc Natl Acad Sci USA 92, 3849-3853 (1995)
86. Sukhova G.K, G.P. Shi, D.I. Simon, H.A. Chapman & P. Libby: Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 102, 576-583 (1998)
87. Jormsjö S, D.M. Wuttge, A. Sirsjö, C. Whatling, A. Hamsten, S. Stemme & P. Eriksson: Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 161, 939-945 (2002)
88. Chen J, C.-H. Tung, U. Mahmood, V. Ntziachristos, R. Gyurko, M.C. Fishman, P.L. Huang & R. Weissleder: In vivo imaging of proteolytic activity in atherosclerosis. Circulation 105, 2766-2771 (2002)
89. Gacko M. & S. Glowinski: Cathepsin D and cathepsin L activities in aortic aneurysm wall and parietal thrombus. Clin Chem Lab Med 36, 449-452 (1998)
90. Shi G.P, G.K. Sukhova, A. Grubb, A. Ducharme, L.H. Rhode, R.T. Lee, P.M. Ridker, P. Libby & H.A. Chapman: Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104, 1191-1197 (1999)
91. Schaub F.J, D.K. Han, W.C. Liles, L.D. Adams, S.A. Coats, R.K. Ramachandran, R.A. Seifert, S.M. Schwartz & D.F. Bowen-Pope: Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nature Med 6, 790-796 (2000)
92. Fazio S, A.S. Major, L.L. Swift, L.A. Gleaves, M. Accad, M.F. Linton & R.V.Jr. Farese: Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 107, 163-171 (2001)
93. Nhan T.Q, W.C. Liles, A. Chait, J.T. Fallon & S.M. Schwartz: The p17 cleaved form of caspase-3 in present within viable macrophages in vitro and in atherosclerotic plaque. Arterioscler Thromb Vasc Biol May 22 [epub ahead of print] (2003)
94. Kubo N, L.K. Curtiss, S. Yamada, H. Kanno, I. Sakurabayashi, K. Itoh & W.A. Boisvert: Role of macrophage apoptosis in atherogenesis. Arterioscler Thromb Vasc Biol 22, p317, Abstr. (2002)
95. Kockx M.M. & A.G. Herman: Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res 45, 736-746 (2000)
96. Rekhter M.D, G.W. Hicks, D.W. Brammer, H. Hallak, E. Kindt, J. Chen, W.S. Rosebury, M.K. Anderson, P.J. Kuipers & M.J. Ryan: Hypercholesterolemia causes mechanical weakening of rabbit atheroma: local collagen loss as a prerequisite of plaque rupture. Circ Res 86, 101-108 (2000)
97. Geng Y.J. & P. Libby: Evidence of apoptosis in advanced human atheroma. Colocalization with interleukin-beta converting enzyme. Am J Pathol 147, 251-266 (1995)
98. McCarthy N.J. & M.R. Bennett: The regulation of vascular smooth muscle apoptosis. Cardiovasc Res 45, 747-755 (2000)
99. Kockx M.M, G.R. De Meyer, N. Buyssens, M.W. Knaapen, H. Bult & A.G. Herman: Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ Res 83, 378-387 (1998)
100. Rong J.X, J. Li, E.D. Reis, R.P. Choudhury, H.M. Dansky, V.I. Elmalem, J.T. Fallon, J.L. Breslow & E.A. Fisher: Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 104, 2447-2452 (2001)
101. Aikawa M, E. Rabkin, Y. Okada, S.J. Voglic, S.K. Clinton, C.E. Brinckerhoff, G.K,. Sukhova & P. Libby: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content in rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97, 2433-2444 (1998)
102. Bennett M.R, G.I. Evan & S.M. Schwartz: Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 95, 2266-2274 (1995)
103. Bennett M.R: Apoptosis in the cardiovascular system. Heart 87, 480-487 (2002)
104. Chu Y, F.M. Faraci, H. Ooboshi & D.D. Heistad: Increase in TUNEL positive cells in aorta from diabetic rats. Endothelium 5, 241-50 (1997)
105. Hall J.L, C. Matter, M.J. Pollman, H.Z. Bai, Y. Inishi & G.H. Gibbons: Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase C-dependent pathway. Circulation 98, 574-580 (2000)
106. Peiro C, N. Lafuente, N. Matesanz, E. Cercas, J.L. Llergo, S. Vallejo, L. Rodriguez-Manas & C.F. Sanchez-Ferrer: High glucose induces cell death of cultured human aortic smooth muscle cells through the formation of hydrogen peroxide. Br J Pharmacol 133, 967-974 (2001)
107. Hall J.L, J.C. Chatham, H. Eldar-Finkelman & G.H. Gibbons: Upregulation of glucose metabolism during intimai lesion formation is coupled to the inhibition of vascular smooth muscle cell apoptosis. Role of GSK3beta. Diabetes 50, 1171-1179 (2001)
108. Sakuma H, M. Yamamoto, M. Okumura, T. Kojima, T. Maruyama & K. Yasuda: High glucose inhibits apoptosis in human coronary artery smooth muscle cells by increasing bcl-xL and bfl-1/A1. Am J Physiol Cell Physiol 283, C422-C428 (2002)
109. Gerrity R.G, R. Natarajan, J.L. Nadler & T. Kimsey: Diabetes-induced accelerated atherosclerosis in swine. Diabetes 50, 1654-1665 (2001)
110. Oldstone M.B, M. Nerenberg, P. Southern, J. Price & H. Lewicki: Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65, 319-331 (1991)
111. von Herrath M.G, J. Dockter & M.B. Oldstone: How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1, 231-242 (1994)
112. Breddin H, H. Krzywanek, P. Althoff, K. Schoffling & K. Ubeila: PARD: Platelet aggregation as a risk factor in diabetes: results of a prospective study. Horm Metab Res 15, 63-68 (1985)
113. Colwell J & M. Lopes-Virella: A review of the development of large vessel disease in diabetes mellitus. Am J Med 85, 113-119 (1988)
114. Ziboh V, H. Maruta, J. Lord, W. Cagle & W. Lucky: Increased biosynthesis of thromboxane A2 by diabetic platelets. Eur J Clin Invest 9, 223-228 (1979)
115. Butkus A, A. Skrinska & O. Schumacher: Thromboxane production and platelet aggregation in diabetic subjects with clinical complications. Thromb Res 19, 211-223 (1980)
116. Lagarde M, M. Burtin, P. Berciaud, M. Blanc, B. Velardo & M. Dechavanne: Increase of platelet thromboxane A2 formation and its plasmatic half-life in diabetes mellitus. Thromb Res 19, 823-830 (1980)
117. Davi G, I. Catalano, M. Averna, A. Notobartolo, A. Strano & G. Ciabottoni: Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322, 1769-1774 (1990)
118. Ostermann H. & J. van de Loo: Factors of the hemostatic system in diabetic patients. Haemostasis 16, 386-416 (1986)
119. Sagel J, J. Colwell, L. Crook & M. Laimans: Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 82, 733-738 (1975)
120. Badawi H, M. El-Sawy, M. Mikhail, A. Nomier & S. Tewfik: Platelets, coagulation in diabetic and nondiabetic patients with quiescent coronary heart disease. Angiology 21, 511-519 (1970)
121. Rosove M, F. Harrison & M. Harwig: Plasma B-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved short-term glycemic control in diabetes mellitus. Diabetes Care 7, 174-179 (1984)
122. Small M, G. Lowe, A. MacCuish & C. Forbes: Thrombin and plasmin activity in diabetes mellitus and their association with glycemic control. Q J Med 248, 1025-1031 (1987)
123. Sobel B.E: Fibrinolysis and diabetes. Front Biosci 8, d1085-1092 (2003)
124. Herlihy O.M, B.A. Barrow, P.J. Grant & J.C. Levy: Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling. Diabetologia 45, 635-641 (2002)
125. Lapolla A, F. Piarulli, G. Sartore, C. Rossetti, L. Martano, P. Carraro, M. De Paoli & D. Fedele: Peripheral artery disease in type 2 diabetes: the role of fibrinolysis. Thromb Haemost 89, 91-96 (2003)
126. Eren M, C.A. Painter, J.B. Atkinson, P.J. Declerck & D.E. Vaughan: Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106, 491-496 (2002)
127. Yuan C, S.X. Zhang, N.L. Polissar, D. Echelard, G. Ortiz, J.W. Davis, E. Ellington, M.S. Ferguson & T.S. Hatsukami: Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 105, 181-185 (2002)
128. Yuan C, W.S. Kerwin, M.S. Ferguson, N. Polissar, S. Zhang, J. Cai & T.S. Hatsukami: Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging 15, 62-67 (2002)
129. Fayad Z.A & V. Fuster: The human high-risk plaque and its detection by magnetic resonance imaging. Am J Cardiol 88, 42E-45E (2001)
130. Hatsukami T.S, R. Ross, N.L. Polissar & C. Yuan: Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation 102, 959-964 (2000)